Stock Scorecard



Stock Summary for Idexx Laboratories Inc (IDXX) - $670.21 as of 11/19/2025 3:32:01 PM EST

Total Score

11 out of 30

Safety Score

59 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for IDXX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for IDXX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for IDXX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for IDXX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for IDXX (59 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 2
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for IDXX

Molina Secures Deal From AHCA to Serve Florida's Medicaid Members 11/17/2025 6:13:00 PM
TFX Stock Falls Despite Q3 Earnings and Revenue Beat, '25 View Down 11/13/2025 1:08:00 PM
ALC's Q3 Earnings Beat, Revenues Miss, Stock Rises in After-Market Hours 11/12/2025 12:13:00 PM
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up 11/11/2025 12:26:00 PM
Peering Into IDEXX Laboratories Inc's Recent Short Interest - IDEXX Laboratories ( NASDAQ:IDXX ) 11/6/2025 2:02:00 PM
STE Stock Gains on Q2 Earnings and Revenue Beat, '26 EPS View Up 11/6/2025 1:29:00 PM
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop 11/5/2025 5:17:00 PM
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours 11/5/2025 4:01:00 PM
TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up 11/5/2025 3:52:00 PM
3 Reasons Why Growth Investors Shouldn't Overlook Idexx ( IDXX ) 11/4/2025 5:45:00 PM

Financial Details for IDXX

Company Overview

Ticker IDXX
Company Name Idexx Laboratories Inc
Country USA
Description IDEXX Laboratories, Inc. is a leading American multinational firm specializing in advanced diagnostics and software solutions for the veterinary, livestock, and water testing industries. Recognized for its innovative technologies, IDEXX enhances the quality of veterinary care and delivers reliable testing solutions to agriculture sectors, thus addressing critical demands in food safety and animal health. With a robust commitment to research and development, the company is well-positioned for continued growth, capitalizing on the increasing global focus on companion animal health and overall food safety. IDEXX's strategic leadership in these areas solidifies its stance as a key player in improving health outcomes across various animal populations.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 9/30/2025
Next Earnings Date 2/3/2026

Stock Price History

Last Day Price 670.21
Price 4 Years Ago 658.46
Last Day Price Updated 11/19/2025 3:32:01 PM EST
Last Day Volume 1,008,906
Average Daily Volume 511,206
52-Week High 735.00
52-Week Low 356.14
Last Price to 52 Week Low 88.19%

Valuation Measures

Trailing PE 53.28
Industry PE 37.18
Sector PE 115.35
5-Year Average PE 57.02
Free Cash Flow Ratio 256.79
Industry Free Cash Flow Ratio 70.90
Sector Free Cash Flow Ratio 27.55
Current Ratio Most Recent Quarter 1.12
Total Cash Per Share 2.61
Book Value Per Share Most Recent Quarter 19.52
Price to Book Ratio 34.22
Industry Price to Book Ratio 243.13
Sector Price to Book Ratio 33.20
Price to Sales Ratio Twelve Trailing Months 12.87
Industry Price to Sales Ratio Twelve Trailing Months 4.81
Sector Price to Sales Ratio Twelve Trailing Months 16.69
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 79,851,000
Market Capitalization 53,516,938,710
Institutional Ownership 95.44%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.73%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 21.40%
Annual Earnings Growth 5.07%
Reported EPS 12 Trailing Months 12.58
Reported EPS Past Year 9.99
Reported EPS Prior Year 10.67
Net Income Twelve Trailing Months 1,027,425,000
Net Income Past Year 887,867,000
Net Income Prior Year 845,042,000
Quarterly Revenue Growth YOY 13.30%
5-Year Revenue Growth 10.12%
Operating Margin Twelve Trailing Months 32.10%

Balance Sheet

Total Cash Most Recent Quarter 208,166,000
Total Cash Past Year 288,266,000
Total Cash Prior Year 453,932,000
Net Cash Position Most Recent Quarter -166,659,000
Net Cash Position Past Year -161,520,000
Long Term Debt Past Year 449,786,000
Long Term Debt Prior Year 622,883,000
Total Debt Most Recent Quarter 374,825,000
Equity to Debt Ratio Past Year 0.78
Equity to Debt Ratio Most Recent Quarter 0.81
Total Stockholder Equity Past Year 1,595,313,000
Total Stockholder Equity Prior Year 1,484,530,000
Total Stockholder Equity Most Recent Quarter 1,561,186,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 953,573,000
Free Cash Flow Per Share Twelve Trailing Months 11.94
Free Cash Flow Past Year 798,079,000
Free Cash Flow Prior Year 772,879,000

Options

Put/Call Ratio 0.94
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 17.84
MACD Signal 17.34
20-Day Bollinger Lower Band 527.20
20-Day Bollinger Middle Band 627.16
20-Day Bollinger Upper Band 727.12
Beta 1.69
RSI 56.62
50-Day SMA 523.30
150-Day SMA 501.37
200-Day SMA 479.65

System

Modified 11/20/2025 1:29:33 AM EST